By contrast another paper implicated the loss of CERT in the progression of triple-negative breast cancer cells, which express cytokeratins 5/6, 14, and 17, lack ER/PR expression and ErbB2/HER2 amplification/overexpression and are especially refractory to treatment [93], thus suggesting that the role of CERT in chemoresistance and cancer progression is still controversial and could strongly depend on the global cancer gene expression profile. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.